Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;155(1):91-104.
doi: 10.4103/ijmr.IJMR_474_21.

Safety & effectiveness of COVID-19 vaccines: A narrative review

Affiliations
Review

Safety & effectiveness of COVID-19 vaccines: A narrative review

Francesco Chirico et al. Indian J Med Res. 2022 Jan.

Abstract

There are currently eight vaccines against SARS-CoV-2 that have received Emergency Use Authorization by the WHO that can offer some protection to the world's population during the COVID-19 pandemic. Though research is being published all over the world, public health officials, policymakers and governments are collecting evidence-based information to establish the public health policies. Unfortunately, continued international travel, violations of lockdowns and social distancing, the lack of mask use, the emergence of mutant strains of the virus and lower adherence by a sector of the global population that remains sceptical of the protection offered by vaccines, or about any risks associated with vaccines, hamper these efforts. Here we examine the literature on the efficacy, effectiveness and safety of COVID-19 vaccines, with an emphasis on select categories of individuals and against new SARS-CoV-2 strains. The literature shows that these eight vaccines are highly effective in protecting the population from severe disease and death, but there are some issues concerning safety and adverse effects. Further, booster shots and variant-specific vaccines would also be required.

Keywords: Adverse effect; COVID-19; SARS-CoV-2; clinical trials; efficacy; neutralization potential; risks; safety.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: None.

Similar articles

Cited by

References

    1. World Health Organization. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process. [accessed on December 20, 2021]. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVI... .
    1. Soiza RL, Scicluna C, Thomson EC. Efficacy and safety of COVID-19 vaccines in older people. Age Ageing. 2021;50:279–83. - PMC - PubMed
    1. Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the cold reality of mRNA vaccine stability. J Pharm Sci. 2021;110:997–1001. - PMC - PubMed
    1. Dolgin E. CureVac COVID vaccine let-down spotlights mRNA design challenges. Nature. 2021;594:483. - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. - PMC - PubMed

Substances